Update on Clinical Trials in Systemic Lupus Erythematosus

Sonali Narain; Richard Furie


Curr Opin Rheumatol. 2016;28(5):477-487. 

In This Article

New Drugs in Trials

Baricitinib, a selective and reversible janus kinase1/2 inhibitor, was effective in rheumatoid arthritis and psoriasis.[91–94] A phase II trial of baricitinib in SLE patients with arthritis and/or rash will commence in 2016. Polymorphisms in transcription factors Ikaros (IKZF1) and Aiolos (IKZF3) have been associated with SLE. A new drug, CC-220, by Celgene is an immunomodulatory compound that ubiquinates IKZF1/3. A phase I clinical trial has demonstrated reduced antibody production in cultures of SLE peripheral blood mononuclear cells.[95] A phase II randomized double-blind placebo-controlled study, to evaluate CC-220 in SLE patients with skin or joint manifestations, is currently ongoing. Lulizumab pegol targets CD28 and is being studied in a phase II dose escalating trial in nonrenal SLE patients. IL-2 plays a key role in the activation and proliferation of T cells. A recent trial[96] reported a 90% SRI response rate at week 6 (n = 40) in patients on low-dose IL-2 therapy. There were no adverse events, and improvements in complement levels, antidsDNA antibody levels and proteinuria were also reported.